TNX-1300
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cocaine Intoxication
Conditions
Cocaine Intoxication
Trial Timeline
Sep 3, 2021 → Jun 16, 2022
NCT ID
NCT04996056About TNX-1300
TNX-1300 is a phase 2 stage product being developed by Tonix Pharmaceuticals for Cocaine Intoxication. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04996056. Target conditions include Cocaine Intoxication.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04996056 | Phase 2 | Withdrawn |
Competing Products
13 competing products in Cocaine Intoxication
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy | Johnson & Johnson | Phase 3 | 77 |
| Topiramate | Johnson & Johnson | Phase 2 | 52 |
| quetiapine | AstraZeneca | Approved | 85 |
| quetiapine fumarate + Matched Placebo | AstraZeneca | Pre-clinical | 23 |
| AFQ056 + Placebo | Novartis | Phase 1 | 33 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| ALKS 33-BUP + ALKS 33 + Placebo | Alkermes | Phase 1 | 30 |
| VIVITROL (Naltrexone extended-release injectable suspension) + Placebo | Alkermes | Phase 2 | 49 |
| vigabatrin + placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| Vigabatrin + Matching Placebo | Catalyst Pharmaceuticals | Phase 2/3 | 60 |
| Vigabatrin + Placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| CPP-115 + Placebo | Catalyst Pharmaceuticals | Phase 1 | 28 |
| TNX-1300 (Injection) + Placebo (Injection) | Tonix Pharmaceuticals | Phase 2 | 44 |